Anavex Life Sciences Achieves Breakthrough in Alzheimer’s Research

Anavex Life Sciences has announced promising results from its recent Phase 2b/3 clinical trial
investigating their novel agent, blarcamesine (ANAVEX2-73), for the treatment
of early-stage Alzheimer’s disease. The trial demonstrated significant
reductions in pathological amyloid-ß levels and a notable slowing of brain
atrophy among participants. 

The study enrolled 508 patients with early symptomatic Alzheimer’s disease from 52 medical centers
across five countries. Participants were randomized to receive either
blarcamesine or a placebo. The primary endpoints were evaluated using the
Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog) and the Alzheimer’s
Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) subscales.
Results indicated a statistically significant improvement in cognitive function
and daily living activities for those treated with blarcamesine. 

According to Anavex Life Sciences, the agent showed a strong antiamyloid effect,
evidenced by significant increases in plasma Aβ42/40 ratio. MRI findings
further supported these outcomes by showing a reduction in brain volume loss,
including whole brain atrophy. This makes blarcamesine one of the first
therapies to demonstrate efficacy on biomarkers of neurodegeneration in Alzheimer’s patients. 

Marwan Noel Sabbagh, MD, a professor of neurology and chairman of the Scientific Advisory
Board at Anavex, noted that blarcamesine’s small oral molecule offers clinical
benefits in cognition and neurodegeneration. Its oral administration route and
excellent safety profile add to its appeal as a potential treatment fo Alzheimer’s. 

The most commonly reported adverse event was dizziness, which was transient and mostly mild to
moderate in severity. Anavex Life Sciences’ CEO, Christopher U Missling, PhD,
expressed gratitude to all study participants and emphasized the company’s
commitment to advancing this promising treatment. 

The success of this trial marks a significant milestone for Anavex Life Sciences, potentially offering a new,
convenient treatment option for patients suffering from Alzheimer’s disease. 

Refer to this article for related information. 

More about Anavex on https://www.cnbc.com/quotes/AVXL